Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roivant Sciences Ltd.

http://roivant.com

Latest From Roivant Sciences Ltd.

Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

Deal Watch Business Strategies

Myovant's Next Act: Commercial Execution And Business Development

The company is ramping up the launches of Orgovyx for prostate cancer and Myfembree for uterine fibroids, including indication and geographic expansions, and evaluating business development opportunities.

Business Strategies Commercial

Wild Ride For Immunology? New Mechanisms, Big Indications Up For US FDA Approval In 2022

Major R&D efforts in immuno-dermatology produced multiple novel candidates in atopic dermatitis and psoriasis, while alopecia areata and vitiligo might see first therapies and JAK safety and COVID-19 logjams resolve.

Immune Disorders Pink Sheet Perspectives

Apollo’s Next Steps: Apply Learnings From Prior Hub-And-Spoke Entities

Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.

Business Strategies Commercial
See All

Company Information

UsernamePublicRestriction

Register